Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | ALPG | P10696 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.53 |
| ▸ | CTSV | O60911 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328384 | 0.92 | MAPT (0.58) | MAPTLMNATDP1L3MBTL1MAPK1 | |
| SCHEMBL4932340 | 0.89 | MAPT (0.73) | MAPTLMNATDP1L3MBTL1MAPK1 | |
| SCHEMBL4930929 | 0.88 | MAPT (0.68) | MAPTLMNATDP1L3MBTL1MAPK1 | |
| SCHEMBL4930639 | 0.87 | L3MBTL1 (0.62) | MAPTLMNATDP1L3MBTL1MAPK1 | |
| SCHEMBL4930700 | 0.86 | MAPT (0.58) | MAPTLMNATDP1L3MBTL1MAPK1 | |
| SCHEMBL4932124 | 0.85 | MAPT (0.63) | MAPTLMNATDP1L3MBTL1HTT | |
| SCHEMBL4932353 | 0.85 | MEN1 (0.60) | MAPTLMNATDP1L3MBTL1MAPK1 | |
| SCHEMBL4933766 | 0.84 | MAPT (0.67) | MAPTLMNATDP1L3MBTL1MAPK1 | |
| SCHEMBL2324309 | 0.84 | L3MBTL1 (0.56) | MAPTLMNATDP1L3MBTL1MAPK1 | |
| SCHEMBL2902330 | 0.83 | MAPT (0.65) | MAPTLMNATDP1L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008114009-A1 | 10H-BENZO(G)PTERDINE-2,4-DIONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CAMBRIDGE ENTERPRISE LTD. (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008114009-A1 | 10H-BENZO(G)PTERDINE-2,4-DIONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CAMBRIDGE ENTERPRISE LTD. (GB) | 2008-09-25 | — | — | WO | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-5661169-A | HAVE AFFINITY FOR VASOPRESSIN AND/OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1997-08-26 | — | — | US | disclosed |
| US-5585394-A | INHIBITOR, ANTAGONIST OF VASOPRESSIN OR OXYTOCIN | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| EP-0694536-A1 | 1-Benzyl-1,3-dihydro-2H-benzimidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-01-31 | — | — | EP | disclosed |
| EP-0636614-A1 | Derivatives of 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | GPR119, INSR, GPR65 | MAPT 4574/4885LMNA 4744/4885TDP1 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.